1. Introduction {#sec1}
===============

Thyroid diseases are more prevalent in women particularly between puberty and menopause \[[@B1]\], and women are more susceptible to the goitrogenic effect of iodine deficiency \[[@B2]\]. Carcinomas of the thyroid are three-times more frequent in women than in men, and the peak rates occur earlier in women \[[@B3]\]. These epidemiological data suggest a role of estrogen in the pathogenesis of thyroid diseases.

Estrogen has a well-known indirect effect on thyroid economy, increasing the thyroxine binding globulin \[[@B4]\], and the need for thyroid hormone in hypothyroid women \[[@B5]\]. Direct effects of estrogen on thyroid cells have been described more recently \[[@B6]\], so the aim of the present paper was to review the evidences of these effects on thyroid function and growth regulation, and its mechanisms.

2. Estrogen and Its Receptors {#sec2}
=============================

17-*β*-estradiol (E2) is a lipophilic hormone with low-molecular weight that occurs naturally. Cellular signaling of estrogen is mediated classically upon the binding on two soluble intracellular nuclear receptors, estrogen receptor (ER) alpha, and ER beta \[[@B7]\]. The isoform *β* is smaller than the isoform *α*, and the DNA-binding domains of both subtypes are highly conserved. After binding of E2, ER forms a stable dimer that interacts with specific sequences called estrogen response elements (EREs) to initiate the transcription of target genes. Ligand-bound ERs can also interact with other transcription factors complexes and influence transcription of genes that do not harbor EREs. Third and fourth mechanisms of ERs regulatory actions are, respectively, non-genomic and the ligand independent pathway. A variety of rapid signaling events such as activation of kinases and phosphatases and increases in ion fluxes across membranes has been described. These and other aspects of signaling and targets of ERs have been reviewed recently \[[@B7]\].

Recently, a transmembrane intracellular nonclassical ER mediating rapid cell signaling was described, a G protein-coupled receptor (GPCR), named GPR30 \[[@B8]\].

2.1. Expression of ERs in Human Thyroid Tissue {#sec2.1}
----------------------------------------------

Classically, the presence of ER is fundamental for a direct action of estrogen in a given cell. ER has been described in both neoplastic and nonneoplastic human thyroid tissues, but the results are discordant. Immunohistochemical assays, with monoclonal antibodies, are the most commonly used methods for establishing receptor status. As may be seen in [Table 1](#tab1){ref-type="table"}, some studies have found ER-positivity in normal and abnormal thyroid tissue while others have not detected ER protein in any tissue studied. This discrepancy could be due to methodological issues; the development of monoclonal antibodies against ER with high sensitivity and specificity, and others factors such as tissue fixation, tissue processing, interpretation of immunohistochemistry, and *cutoffs* for positive results, could have contributed to the sensitivity of the techniques employed \[[@B9]\].

2.2. Expression of ER*α* and ER*β* in Human Thyroid Tissue {#sec2.2}
----------------------------------------------------------

ER expression in human thyroid was first reported in 1981 \[[@B10]\]. ER*α* was first described in 1973 \[[@B11]\], and ER*β* was identified in 1996 \[[@B12]\], so only from this moment on it was possible to evaluate the relationship between isoforms of ERs in thyroid tissue. An important role of different patterns of distribution and expression of subtypes ERs in thyroid carcinoma has been proposed: estrogen binding to ER*α* would promote cell proliferation and growth, and, in contrast, ER*β* would promote apoptotic actions and other suppressive functions in thyroid tumors, as reviewed by Chen et al. \[[@B13]\]. Then, ER*α* : ER*β* ratio could have a role in the pathophysiology of thyroid cancer \[[@B13]\], similar to that postulated for breast cancer \[[@B14]\].

In differentiated thyroid follicular tumors, the expression of ER*α* has been associated with well-differentiated tumors and reduced incidence of disease recurrence \[[@B15]\]. ER*α* protein \[[@B16]\] and ER*α* mRNA \[[@B17], [@B18]\] are expressed in normal and neoplastic follicular cells of the thyroid. Also, the expression of ER*α* and ER*β* was detected in human medullary thyroid cancer \[[@B19]\] with an increased ratio of ER*α*/ER*β*, suggesting a possible role in tumor growth and progression. A few studies evaluated ER*α* and ER*β* expression in normal and abnormal thyroid tissue, as shown in [Table 2](#tab2){ref-type="table"}.

The effects of the agonists of ER*α* and ER*β*, respectively, propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN), in the proliferation of thyroid cancer cell lines has been studied: PPT had a stimulatory effect, while inhibition of proliferation and DNA fragmentation were observed after DPN \[[@B20]\]. In the same study, small interference ribonucleic acid (siRNA) blocking ER*α* or ER*β* demonstrated that knockdown of the ER*α* attenuated E2-mediated B-cell lymphoma 2 (Bcl-2) expression, an important antiapoptotic protein, while knockdown of the ER*β* enhanced E2-induced Bcl-2 expression \[[@B20]\].

2.3. Expression of GPR30 in Thyroid Cells Lines {#sec2.3}
-----------------------------------------------

Growing evidence suggests that estrogens are also able to exert non-genomic events mediated by GPR30 \[[@B8]\]. Vivacqua and colleagues analyzed the effects of E2 and the phytoestrogen genistein in human follicular thyroid carcinoma cell lines, WRO and FRO, and ARO, a human anaplastic thyroid carcinoma cell line \[[@B21]\]. Both hormones stimulated *in vitro* proliferation of these cell lines through the GPR30 and mitogen-activated protein kinase signaling cascade \[[@B21]\]. In other human benign and malignant thyroid tissue, the expression of GPR30 has not been studied.

3. Response to E2 Stimulation *In Vitro* {#sec3}
========================================

3.1. Proliferation {#sec3.1}
------------------

Several studies described proliferation of thyroid cells induced by E2, as shown in [Table 3](#tab3){ref-type="table"}. Some of the most commonly used assays are incorporation of bromodeoxyuridine (BrdU) \[[@B6]\], 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) \[[@B20], [@B23], [@B22], [@B24]\], \[(3)H\]-thymidine incorporation \[[@B25], [@B26], [@B27]\], and trypan blue solution \[[@B28]\]. Cotreatment with ICI182780, fulvestrant, an antagonist of E2 by inhibition and degradation of ER \[[@B29]\], significantly attenuated these proliferative effects.

Based in these studies, E2 increases proliferation of thyroid cells.

3.2. ER-Dependent Effects on Thyroid Differentiation Proteins {#sec3.2}
-------------------------------------------------------------

Few studies evaluated E2 effect on gene transcription of differentiation proteins in thyroid cells. In Fischer rat derived thyroid cell line, FRTL-5, E2 treatment decreased the sodium-iodide symporter (NIS) gene expression \[[@B22]\], and the iodide uptake \[[@B30]\]. E2 increased the thyroglobulin gene expression in suspension cultures of human thyroid follicles of adenoma and carcinoma \[[@B26]\]. These data are shown in [Table 3](#tab3){ref-type="table"}. The opposite effects of E2 on the NIS gene expression and iodide uptake, in FRTL-5 cells, and the thyroglobulin gene expression, in suspension culture of thyroid cells, could be due to the different systems studied; it cannot be excluded that estradiol affects these genes by different intracellular pathways. These results, together with the increase in cell growth caused by estrogen, could implicate this hormone in the pathogenesis of goiter and thyroid carcinoma; nevertheless, as just one study evaluated the effect of estrogen on thyroid differentiated proteins in human thyroid tissue, more studies should be done to better understand the role of estrogen in thyroid differentiated protein expression.

3.3. Non-Genomic Effects of E2 {#sec3.3}
------------------------------

Some of the actions of E2 in the proliferation of thyroid cells are mediated by the activation of signal transducing pathways, as shown in [Table 4](#tab4){ref-type="table"}. E2 can induce activation of phosphatidylinositol 3-kinase (PI3K) \[[@B31]\] and phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) in follicular thyroid carcinoma cells, mainly due to interaction via membrane-associated ER \[[@B31], [@B20], [@B21]\]. PI3K and Erk1/2 signaling may play a critical role in preventing apoptosis and inducing cell cycle progression by induction of key genes expression \[[@B32]\].

Expression of early response genes and regulatory genes of the cell cycle are necessary for proliferation of cells. As E2 has been demonstrated to stimulate the growth of thyroid cells, it is important to study the expression of key cell-cycle genes such as cyclin D1 after stimulation with E2. Cyclin D1 regulates the cell progression cycle facilitating G~1~ to S phase transition and also has an estrogen-responsive regulatory region \[[@B33]\], that is likely different from the canonical EREs. Overexpression of cyclin D1 in thyroid malignancies has been reported \[[@B34]--[@B38]\], moreover, its expression has been associated with an aggressive behavior in papillary thyroid microcarcinomas, because over 90% of the metastasizing microcarcinomas expressed cyclin D1 \[[@B39]\].

E2 significantly increased the expression of cyclin D1 in a human thyroid carcinoma cell line lacking endogenous TSH receptor (HTC-TSHr cells), and in a thyroid cancer cell line of Hurthle cell origin (XTC-133), which was abolished by PD.098059 that blocked G0/G1 to S phases \[[@B6]\]. E2 upregulated cyclins A and D1, as well as the proto-oncogene *c-fos*, in WRO, FRO, and ARO cells \[[@B21]\]. Cyclin D1 was also shown to be upregulated by E2 in KAT5, a papillary thyroid cancer cell line, and WRO cells \[[@B31]\].

Together, these results are very compelling, pointing to an ability of E2 to regulate genes mediating cell cycle progression in thyroid cells, and potentially contributing to the pathogenesis of thyroid cancer or thyroid hyperplasia.

4. Conclusions {#sec4}
==============

There are evidences that estrogen may have direct actions in human thyroid cells by ER-dependent mechanisms or not, modulating proliferation, and function. Different patterns of distribution, expression, and ratios of ER*α* and ER*β* may have a role in thyroid cancer cells proliferation, as well as in the outcome of thyroid cancer. Studying estrogen effects on thyroid cells is a potential tool to better understand the pathogenesis of thyroid diseases, and to develop targets to its treatment. Further studies on the influence of E2 on the growth and function of the thyroid are needed, preferably in primary culture of normal and abnormal human thyroid cells.
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###### 

Estrogen receptor (ER) in human normal thyroid, and benign and malignant thyroid diseases.

  Study                                 Method   Normal   All benign lesions   All neoplastic lesions   All carcinoma   Benign lesions   Carcinoma                           
  ------------------------------------- -------- -------- -------------------- ------------------------ --------------- ---------------- ----------- -------- ------- ------ ------
  Tavangar et al. \[[@B40]\]; 2007      IHC                                                                             8/37             31/130      37/119   2/18    0/35   0/12
  Arain et al. \[[@B41]\]; 2003         IHC      0/25                                                                   0/9              0/8         0/19     0/10    0/4    
  Lewy-Trenda et al. \[[@B42]\]; 1998   IHC                                                                             2/19             0/20        4/8      3/5            0/4
  Valle et al. \[[@B43]\]; 1998         RT-PCR   28/33                                                                  12/12            6/7         26/26    1/1     1/1    1/1
  Bonacci et al. \[[@B44]\]; 1996       DCC      26/38    11/28                                         7/20                                                                 
  Jaklic et al. \[[@B45]\]; 1995        IHC                                                                             0/1              0/5         0/4              0/1    
  Colomer et al. \[[@B46]\]; 1996       IHC                                                                                                                           1/7    
  Inoue et al. \[[@B47]\]; 1993         IHC                                                                                                          24/74                   
  Inoue et al. \[[@B48]\]; 1993         IHC                                                                                                          18/70                   
  Yane et al. \[[@B17]\]; 1994          RT-PCR                                 5/27                                                                                          
  Yane et al. \[[@B49]\]; 1993          IHC      0/10                                                   2/19            2/12             0/7                                 
  Hiasa et al. \[[@B50]\]; 1993         IHC                                                                             44/130           23/39       19/115   7/23           0/6
  Diaz et al. \[[@B51]\]; 1991          IHC                                                                             20/30                        23/30    11/20          
  Mizukami et al. \[[@B52]\]; 1991      IHC               8/18                                                          4/8                          47/62                   
  Takeichi et al. \[[@B53]\]; 1991      IHC                                                                                                          11/12                   1/6
  Hong et al. \[[@B54]\]; 1991          IHC                                                                                                          1/27     1/20           
  Miki et al. \[[@B55]\]; 1990          DCC      0/14     12/46                                         7/23            5/11             2/12        6/20     0/1            1/1
  Haruta et al. \[[@B56]\]; 1990        IHC                                                                                                          30/52                   0/12
  Chaudhuri et al. \[[@B57]\]; 1989     SDG      3/8                                                                    7/9              5/23        8/8      0/6            
  Money et al. \[[@B58]\]; 1989         IHC               20/22                                                                                                              
  Clark et al. \[[@B59]\]; 1985         SDG                                    14/15                                                                                         
  Hampl \[[@B45]\]; 1985                RBA      0/8                                                    0/5                                                                  
  Molteni et al. \[[@B10]\]; 1981       SDG      0/2                                                                                                 2/4                     

Data are shown as number of ER-positive samples/total number of samples. IHC: immunohistochemical assay; DCC: dextran-coated charcoal assay; RT-PCR: reverse transcriptase-polymerase chain reaction technique; SDG: sucrose density gradient assay; RBA: radioligand binding assay.

###### 

Estrogen receptors (ER) *α* and *β* in human normal thyroid, and benign and malignant thyroid diseases, by immunohistochemistry (IHC).

  Study                               Isoform   All benign   All carcinoma   Benign lesions   Carcinoma                         
  ----------------------------------- --------- ------------ --------------- ---------------- ----------- ------- ----- ------- -----
  Vaiman et al. \[[@B60]\]; 2010      ER*α*                                  0/34             0/150       0/90    0/6   0/4     0/5
                                      ER*β*                                  30/34            126/150     60/90   4/6   3/4     3/5
  Winters et al. \[[@B61]\]; 2010     ER*α*                                                               1/1                   
  Vannucchi et al. \[[@B62]\]; 2010   ER*α*                  12/38                                                              
  Cho et al. \[[@B19]\]; 2007         ER*α*                                                                             10/11   
                                      ER*β*                                                                             8/11    
  Bléchet et al. \[[@B63]\]; 2007     ER*α*                                                                             0/28    
                                      ER*β*                                                                             26/28   
  Ceresini et al. \[[@B64]\]; 2006    ER*α*                                                   0/17        0/17                  
                                      ER*β*                                                   17/17       14/17                 

Data are shown as number of ER-positive samples/total number of samples.

###### 

E2 effects on thyroid protein expression, function, and proliferation *in vitro.*

  Study                                   Thyroid cells   Presence of ER*α*/ER*β*   Er*α* expression   Er*β* expression   Proliferation   Nis expression   Iodide uptake   TG mRNA
  --------------------------------------- --------------- ------------------------- ------------------ ------------------ --------------- ---------------- --------------- ---------
  Kumar et al. \[[@B31]\]; 2010           NPA87           ER*α*+/ER*β*+                                                   ↑                                                
                                          KAT5            ER*α*+/ER*β*+                                                   ↑                                                
                                          WRO             ER*α*+/ER*β*+                                                   ↑                                                
  Rajoria et al. \[[@B28]\]; 2010         BCPAP           ER*α*+/ER*β*+                                                   ↑                                                
                                          Nthy-3-1        ER*α*+/ER*β*+                                                   ↑                                                
  Zeng et al. \[[@B65]\]; 2008            KAT5            ER*α*+/ER*β*+             ↑                  0                  ↑                                                
                                          FRO             ER*α*+/ER*β*+             0                  ↑                  ↓                                                
  Zeng et al. \[[@B20]\]; 2007            KAT5            ER*α*+/ER*β*+             ↑                  0                  ↑                                                
                                          FRO             ER*α*+/ER*β*+             ↑                  ↑                  ↑                                                
                                          ARO             ER*α*+/Er*β*+             ↑                  0                  ↑                                                
  Vivacqua et al. \[[@B21]\]; 2006        WRO             ER*α*+/ER*β*−                                                   ↑                                                
                                          FRO             ER*α*+/ER*β*−                                                   ↑                                                
                                          ARO             ER*α*−/ER*β*−                                                   ↑                                                
  Lee et al. \[[@B23]\]; 2005             KAT5                                                                            ↑                                                
  Banu et al. \[[@B25]\]; 2001            NPA87           ER+                       ↑                  ↑                                                                   
                                          WRO             ER+                                                             ↓                                                
  Manole et al. \[[@B6]\]; 2001           HTC-TSHr        ER*α*+/ER*β*+             ↑                  ↑                  ↑                                                
                                          Goiter          ER*α*+/ER*β*+             ↑                  ↑                  ↑                                                
                                          XTC 133                                                                         ↑                                                
  Furlanetto et al. \[[@B30]\]; 2001      FRTL-5                                                                          ↑                                ↓               
  Furlanetto et al. \[[@B22]\]; 1999      FRTL-5          ER*α*+                                                          ↑               ↓                                
  Nagy et al. \[[@B66]\]; 1999\*          Mng                                                                             ↑                                                
                                          Ca                                                                              ↑                                                
                                          Ade                                                                             ↓                                                
  Del Senno et al. \[[@B26]\]; 1989\*\*   N                                                                               ↑                                                ↑
                                          Ade                                                                             ↑                                                ↑
                                          Ca                                                                              0                                                0
  Yang et al. \[[@B27]\]; 1988            TT                                                                              ↑                                                

Estrogen receptor (ER) +: presence of expression, --: absence of expression; NPA87, KAT5, and BCPAP: human papillary thyroid carcinoma cell lines; WRO and FRO: human follicular thyroid carcinoma cell lines; Nthy-3-1: human normal transformed thyroid cell line; ARO: human anaplastic thyroid carcinoma cell line; HTC-TSHr: human thyroid carcinoma cell line lacking endogenous TSH receptor; XTC-133: thyroid cancer cell line of Hurthle cell origin; FRTL-5: Fischer rat thyroid cell line. Mng: multinodular goiter; Ca: carcinoma; Ade: adenoma; N: normal thyroid; TT: human medullary thyroid carcinoma cell line; ↑: increase, ↓: decrease, and 0: no effect, after E2 exposure. \*: thyroid tissue obtained in surgical resection, under organotypic culture conditions for 48 hours; \*\*: suspension cultures of thyroid follicles.

###### 

Non-genomic estrogen effects on thyroid cells.

  Study                              Cells      GPR30   MAPK   PI3k   Cyclin D1   *c-fos*   BcL-2   Bax
  ---------------------------------- ---------- ------- ------ ------ ----------- --------- ------- -----
  Kumar et al. \[[@B31]\]; 2010      NPA87      −       ↑      ↑                                    
                                     KAT5       −       ↑      ↑      ↑                             
                                     WRO        \+      ↑      ↑      ↑                             
  Zeng et al. \[[@B20]\]; 2007       KAT5                                                   ↑       ↓
                                     FRO                                                    ↑       ↓
                                     WRO                                                    ↑       ↓
  Vivacqua et al. \[[@B21]\]; 2006   WRO        \+      ↑             ↑           ↑                 
                                     FRO        \+      ↑             ↑           ↑                 
                                     ARO        \+      ↑             ↑           ↑                 
  Manole et al. \[[@B6]\]; 2001      HTC-TSHr           ↑             ↑                             
                                     Goiter             ↑             ↑                             
                                     XTC 133            ↑             ↑                             

NPA87 and KAT5: human papillary thyroid carcinoma cell lines; WRO and FRO: human follicular thyroid carcinoma cell lines; HTC-TSHr: human thyroid carcinoma cell line lacking endogenous TSH receptor; XTC-133: thyroid cancer cell line of Hurthle cell origin; Goiter: primary culture of human thyroid cells isolated from goiter nodules. (+): presence of expression; (−) absence of expression; (↑): increase, (↓): decrease, and (0): no effects, after E2 exposure.
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